Clinical Trial Update: Celecoxib and Docetaxel or Pemetrexed in Treating Patients With Advanced Recurrent Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating celecoxib with docetaxel or pemetrexed in advanced recurrent non-small cell lung cancer was terminated, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Celecoxib (Celecoxib)
• DOCETAXEL (DOCETAXEL)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: Vanderbilt-Ingram Cancer Center | Conditions: Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2014-10-09